GenEcon Inc.                                News Release

Tuesday, October 14^th, 2003

F O R   I M M E D I A T E   R E L E A S E

GenEcon asked: ‘Cloning…Are humans next?’

GenEcon conducts research on molecular structures in plants, domestic animals, and humans.  It is our hope to expand the body of knowledge in this area and apply our findings to the development of new medical treatments.

“Here, at GenEcon, we believe that the search for new knowledge is always worthwhile,” said CEO Glen Kowan.  “Every discovery that we make is important.”

Scientists at GenEcon are currently working on three areas of major research:

• Completing the sequencing of the DNA of Droso-Phila and C. Elegans.  This research is significant because of the similarities of the genes to those of humans.  Upon completion, these sequences could lead to dramatic advances in the treatment of human diseases.

• Using microchip technology to study the differences in healthy and unhealthy tissue.  Advances made in this field can help us to understand the causes of diseases.  This knowledge will greatly improve the chances of developing vaccines and cures for diseases such as SARS and West Nile.

• Researching family trees in isolated communities in order to better understand complex illnesses such as heart disease and diabetes.

The focus of research at GenEcon is on the possibilities that exist for therapeutic cloning (i.e. technology used to prevent rejection of organs and skin tissue) and the improvement of medical treatments for existing diseases.  While it is believed that we will eventually be able to grow organs for transplant into human subjects, GenEcon does not intend to fully clone humans.  Current technology and limited information make it impossible to successfully clone a human.  Such action also contravenes current state laws.

-30-

Contact:   Peter Turkington
                Corporate Communications
                Direct Line:  123-456-4569
                [email protected]